ABSTRACT
Many emerging technologies often overpromise and underdeliver in the early days of their evolution. Recent examples include combinatorial chemistry, ultra-high throughput screening, and even the promise of genomics to impact drug discovery. The field of docking and virtual screening (VS) for drug discovery has been no different in this regard, but has attained a level of maturity and utility based upon incremental improvements in methods and in our understanding of how and when to best apply these methods.
